<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735462</url>
  </required_header>
  <id_info>
    <org_study_id>GW01-0805</org_study_id>
    <nct_id>NCT00735462</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts</brief_title>
  <official_title>A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graceway Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether imiquimod creams are effective in treating
      external genital warts (EGW). The secondary objective of this study is to provide information
      on recurrence of EGW. Additionally the study will also look at any adverse events associated
      with the use of the creams.

      External genital and perianal warts are caused by the infection of human papillomavirus or
      HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like
      small flesh-colored, pink, or red growths on or around the external skin of sex organs or
      perianal area. The warts may look similar to the small parts of a cauliflower or they may be
      very tiny and difficult to see. They often appear in clusters of three or four, and may grow
      and spread rapidly. They usually are not painful, although they may cause mild pain,
      bleeding, and itching.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The complete clearance was defined as completely cleared all warts including baseline and newly emerged during the study at all anatomic areas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Treatment Related Adverse Reactions (AEs), Any Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Treatment related defined as &quot;probably related&quot; or &quot;related&quot; by investigator. Local skin reactions (LSRs)were part of the treatment related adverse events and assessed by the investigators.
Rest periods defined as temporary interruption of dosing due to intolerable local skin reaction.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>2.5% imiquimod cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5% imiquimod cream applied daily to wart areas for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.75% imiquimod cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream applied daily to wart areas for up to 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.5% imiquimod cream</intervention_name>
    <description>2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.</description>
    <arm_group_label>2.5% imiquimod cream</arm_group_label>
    <other_name>2.5% imiquimod topical cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3.75% imiquimod cream</intervention_name>
    <description>3.75% imiquimod cream applied daily to wart areas for up to 8 weeks</description>
    <arm_group_label>3.75% imiquimod cream</arm_group_label>
    <other_name>3.75% imiquimod topical cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>Placebo cream applied daily to wart areas for up to 8 weeks</description>
    <arm_group_label>Placebo cream</arm_group_label>
    <other_name>Placebo topical cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good general health

          -  Diagnosis of external genital / perianal warts with at least 2 warts and no more than
             30 warts

          -  Negative pregnancy test (for women who are able to become pregnant)

        Exclusion Criteria:

          -  Women who are pregnant, lactating or planning to become pregnant during the study

          -  Evidence of clinically significant or unstable disease (such as stroke, heart attack)

          -  Have any of the following conditions: HIV infection; current or history of high risk
             HPV infection (e.g., HPV types 16, 18, etc.); outbreak of herpes genitalia in the wart
             areas; internal warts requiring or undergoing treatment; dermatological disease (e.g.,
             psoriasis) or skin condition in the wart areas

          -  Have received specific treatments in the treatment area(s) within the designated time
             period prior to study treatment initiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Wu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Graceway Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NEA Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Claifornia Research</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California State University - Chico</name>
      <address>
        <city>Chico</city>
        <state>California</state>
        <zip>95929</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conant Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Healthcare</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMI Health Research Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Women's Research Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Brown</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's OB/GYN</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Research Institute</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Women's Research</name>
      <address>
        <city>Delran</city>
        <state>New Jersey</state>
        <zip>08075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Clinical Research</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boro Park ObGyn</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Medical Research</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complete Healthcare for Women</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State University</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Health Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westover Heights Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Clinical Research</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adams Patterson Gynecology and Obstetrics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Women's Care</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DiscoveResearch</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMC Life Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Clinical Trials</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE-ID</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Clinical Reseach</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independence Family Medicine Clinical Research</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>April 24, 2011</results_first_submitted>
  <results_first_submitted_qc>June 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2011</results_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jason Wu, MD / Executive Director, Product Development</name_title>
    <organization>Graceway Pharmaceuticals</organization>
  </responsible_party>
  <keyword>external genital warts</keyword>
  <keyword>perianal warts</keyword>
  <keyword>condylomata acuminata</keyword>
  <keyword>human papilloma virus</keyword>
  <keyword>HPV types 6 and 11</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2.5% Imiquimod Cream</title>
          <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>3.75% Imiquimod Cream</title>
          <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="204"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2.5% Imiquimod Cream</title>
          <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>3.75% Imiquimod Cream</title>
          <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="204"/>
            <count group_id="B3" value="105"/>
            <count group_id="B4" value="511"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="10.1"/>
                    <measurement group_id="B2" value="32.8" spread="11.0"/>
                    <measurement group_id="B3" value="33.3" spread="10.8"/>
                    <measurement group_id="B4" value="33.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.</title>
        <description>The complete clearance was defined as completely cleared all warts including baseline and newly emerged during the study at all anatomic areas.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2.5% Imiquimod Cream</title>
            <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>3.75% Imiquimod Cream</title>
            <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream applied once daily to wart areas for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.</title>
          <description>The complete clearance was defined as completely cleared all warts including baseline and newly emerged during the study at all anatomic areas.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.248" lower_limit="0.190" upper_limit="0.313"/>
                    <measurement group_id="O2" value="0.294" lower_limit="0.233" upper_limit="0.362"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.040" upper_limit="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Treatment Related Adverse Reactions (AEs), Any Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period</title>
        <description>Treatment related defined as &quot;probably related&quot; or &quot;related&quot; by investigator. Local skin reactions (LSRs)were part of the treatment related adverse events and assessed by the investigators.
Rest periods defined as temporary interruption of dosing due to intolerable local skin reaction.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Analysis population was based on safety population which defined as for all subjects randomized and received at lease one dose. There was one subject who randomized to the 2.5% group but received one treatment kit of 3.75% imiq cream, so this subject was assigned to 3.75% for the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5% Imiquimod Cream</title>
            <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>3.75% Imiquimod Cream</title>
            <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream applied once daily to wart areas for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Treatment Related Adverse Reactions (AEs), Any Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period</title>
          <description>Treatment related defined as &quot;probably related&quot; or &quot;related&quot; by investigator. Local skin reactions (LSRs)were part of the treatment related adverse events and assessed by the investigators.
Rest periods defined as temporary interruption of dosing due to intolerable local skin reaction.</description>
          <population>Analysis population was based on safety population which defined as for all subjects randomized and received at lease one dose. There was one subject who randomized to the 2.5% group but received one treatment kit of 3.75% imiq cream, so this subject was assigned to 3.75% for the safety analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with and Adverse Reactions (ARs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Any Local Skin Reactions (LSRs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects who Took a Rest Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year</time_frame>
      <desc>The study period included 4 month enrollment, maximum 28 weeks of study phase, so total length of the study from first patient enrolled to last patient completed the study is about 11 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>2.5% Imiquimod Cream</title>
          <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>3.75% Imiquimod Cream</title>
          <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo cream applied once daily to wart areas for up to 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="201"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Application site ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Application site bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>a term restricts that PI can publish their trial results within 12 months of completion of the trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was a high percentage of lost to follow up in this study. Since the disease studied in this study can be wait and watch, typically a high lost to follow up rate were seen in these kind of trials.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Babilon, Vice President, Product Development</name_or_title>
      <organization>Graceway Pharmaceuticals</organization>
      <phone>267-948-0400 ext 20428</phone>
      <email>robert.babilon@gracewaypharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

